On January 13, 2020, Fusion Pharmaceuticals announced it has received a commitment of up to US$20 million from the Canada Pension Plan Investment Board. The funding will be used to invest in new partnerships to expand the use of its platform which can create novel cancer treatments. The financing will also be used to target molecules that could lead to new treatments and be put towards the company’s lead clinical candidate, which is currently in a Phase 1 trial for treating solid tumors.
Fusion Pharmaceuticals is a growth stage firm specializing in biopharmaceutical precision oncology. Fusion Pharmaceuticals is focused on creating a safer and more effective form of radiation therapy by developing targeted alpha therapeutics.
The Canada Pension Plan Investment Board is an investment management organization specialized in making investments on behalf of Canadian contributors and beneficiaries, and holds investments in private equity, public equity, and real estate in 52 countries.
Osler, Hoskin & Harcourt LLP advised Fusion Pharmaceuticals with a team consisting of Chad Bayne, Michael Grantmyre and Sahil Chopra (Emerging and High Growth Companies).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Associate, Emerging and High Growth Companies, Toronto
Partner, Emerging and High Growth Companies, Calgary
